Cited 0 times in

Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045

Authors
 Yoo-Na Kim  ;  Je-Gun Joung  ;  Eunhyang Park  ;  Jae-Weon Kim  ;  Jung Bok Lee  ;  Jinyeong Lim  ;  Sunghoon Kim  ;  Chel Hun Choi  ;  Hee Seung Kim  ;  Jongsuk Chung  ;  Byoung-Gie Kim  ;  Jung-Yun Lee 
Citation
 INTERNATIONAL JOURNAL OF CANCER, Vol.154(4) : 764-765, 2024-02 
Journal Title
INTERNATIONAL JOURNAL OF CANCER
ISSN
 0020-7136 
Issue Date
2024-02
MeSH
Antineoplastic Combined Chemotherapy Protocols / adverse effects ; Carcinoma, Ovarian Epithelial ; Female ; Humans ; Neoplasm Recurrence, Local / drug therapy ; Ovarian Neoplasms* / drug therapy ; Ovarian Neoplasms* / genetics ; Phthalazines / adverse effects
Full Text
https://onlinelibrary.wiley.com/doi/10.1002/ijc.34786
DOI
10.1002/ijc.34786
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sung Hoon(김성훈) ORCID logo https://orcid.org/0000-0002-1645-7473
Kim, Yoo‐Na(김유나)
Park, Eunhyang(박은향) ORCID logo https://orcid.org/0000-0003-2658-5054
Lee, Jung-Yun(이정윤) ORCID logo https://orcid.org/0000-0001-7948-1350
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/204225
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links